NASDAQ:ARNA Arena Pharmaceuticals - ARNA Stock Forecast, Price & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Arena Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Add Compare Share Share Today's Range$99.99▼$99.9950-Day Range$93.13▼$99.9952-Week Range$45.50▼$100.00Volume107 shsAverage Volume1.56 million shsMarket Capitalization$6.17 billionP/E RatioN/ADividend YieldN/APrice Target$100.00 ProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Arena Pharmaceuticals MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside0.0% Upside$100.00 Price TargetShort InterestN/ADividend StrengthN/ASustainability-0.78Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($8.32) to ($6.78) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.24 out of 5 starsMedical Sector1026th out of 1,055 stocksPharmaceutical Preparations Industry501st out of 519 stocks 1.0 Analyst's Opinion Consensus RatingArena Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $100.00, Arena Pharmaceuticals has a forecasted upside of 0.0% from its current price of $99.99.Amount of Analyst CoverageArena Pharmaceuticals has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for ARNA. Previous Next 0.0 Dividend Strength Dividend YieldArena Pharmaceuticals does not currently pay a dividend.Dividend GrowthArena Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreArena Pharmaceuticals has received a 73.66% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physiological diseases ", "Preclinical research services for physical health", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Arena Pharmaceuticals is -0.78. Previous Next 0.6 News and Social Media Coverage Search Interest1 people have searched for ARNA on MarketBeat in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Arena Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.41% of the stock of Arena Pharmaceuticals is held by insiders.Percentage Held by Institutions83.77% of the stock of Arena Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Arena Pharmaceuticals are expected to grow in the coming year, from ($8.32) to ($6.78) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arena Pharmaceuticals is -9.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arena Pharmaceuticals is -9.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArena Pharmaceuticals has a P/B Ratio of 9.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Arena Pharmaceuticals (NASDAQ:ARNA) StockArena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. The company's investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, Phase IIb/III clinical trial for Crohn's disease, Phase II clinical trial for alopecia areata, Phase III clinical trial for atopic dermatitis, and Phase IIb clinical trial for eosinophilic esophagitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; APD418 that is in Phase II clinical trial for acute heart failure; and Temanogrel for coronary microvascular obstruction that is in Phase II clinical trial. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Eisai Co., Ltd. and Eisai Inc.; Boehringer Ingelheim International GmbH; Beacon Discovery, Inc.; and Aristea Therapeutics, Inc. Arena Pharmaceuticals, Inc. was incorporated in 1997 and is based in Park City, Utah. As of March 11, 2022, Arena Pharmaceuticals, Inc. operates as a subsidiary of Pfizer Inc.Read More Receive ARNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arena Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ARNA Stock News HeadlinesAugust 23, 2022 | thestreet.comObesity Drugs: The Road to PerditionAugust 9, 2022 | baystreet.caPfizer to Buy Global Blood TherapeuticsJanuary 28, 2023 | Porter & Company (Ad)Is This The End of Capitalism?EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…August 4, 2022 | forbes.comShould You Buy Pfizer Stock After An Upbeat Q2?June 29, 2022 | forbes.comShould You Buy, Sell, Or Hold Pfizer Stock At $52?May 3, 2022 | theglobeandmail.com7 Biotech Stocks With Key Catalysts in MarchMarch 10, 2022 | seekingalpha.comPfizer confirms HSR waiting period for Arena Pharmaceuticals deal expiredMarch 7, 2022 | seekingalpha.comArena Pharma gains after report Pfizer deal will clear without HSR second requestJanuary 28, 2023 | Porter & Company (Ad)Is This The End of Capitalism?EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…February 25, 2022 | seekingalpha.comArena Pharmaceuticals GAAP EPS of -$2.54 misses by $0.31February 24, 2022 | msn.comArena (ARNA) Q4 Loss Wider Than Expected, Etrasimod in FocusFebruary 23, 2022 | uk.finance.yahoo.comSFO opens criminal probe into collapse of Arena TelevisionFebruary 23, 2022 | finance.yahoo.comArena Reports Fourth Quarter and Full Year 2021 Financial Results and Key Program UpdatesFebruary 9, 2022 | finance.yahoo.comArena Pharmaceuticals to Release Fourth Quarter and Full-Year 2021 Financial Results and Provide Corporate Update on February 23February 9, 2022 | benzinga.comHC Wainwright & Co. Downgrades Arena Pharmaceuticals to Neutral, Lowers Price Target to $100February 9, 2022 | markets.businessinsider.comExpert Ratings For Arena PharmaceuticalsFebruary 8, 2022 | nasdaq.comNotable Tuesday Option Activity: ARNA, MSGE, POWWFebruary 6, 2022 | finance.yahoo.comDid The Smart Money Play Arena Pharmaceuticals, Inc. (ARNA) Correctly?February 2, 2022 | finance.yahoo.comIntegral Health Asset Management, LLC Buys McKesson Corp, Centene Corp, Abbott Laboratories,January 31, 2022 | finance.yahoo.comHavens Advisors Llc Buys BHP Group PLC, CyrusOne Inc, NeoPhotonics Corp, Sells , ,January 22, 2022 | msn.com3 Clinical Trials to Watch in the First Half of 2022January 18, 2022 | finance.yahoo.comArena (ARNA) Stock Up in 6 Months on PFE Merger Deal & PipelineJanuary 8, 2022 | nasdaq.comArena Pharmaceuticals Inc Shares Close in on 52-Week High - Market MoverJanuary 3, 2022 | fool.comIs Pfizer's Acquisition of Arena a Good Move for Investors?January 3, 2022 | finance.yahoo.comAre Options Traders Betting on a Big Move in Arena (ARNA) Stock?December 23, 2021 | finance.yahoo.comPfizer’s Arena Pharma deal may lead drug company to a cannabis-based treatmentDecember 22, 2021 | finance.yahoo.comShould You Buy Arena Pharmaceuticals, Inc. (ARNA) After Golden Cross?See More Headlines Receive ARNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arena Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ARNA Company Calendar Last Earnings11/04/2021Today1/28/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical Preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:ARNA CUSIP04004710 CIK1080709 Webwww.arenapharm.com Phone(858) 453-7200Fax858-453-7210Employees448Year Founded1977Price Target and Rating Average Stock Price Forecast$100.00 High Stock Price Forecast$100.00 Low Stock Price Forecast$100.00 Forecasted Upside/Downside+0.0%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($10.13) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-616,430,000.00 Net MarginsN/A Pretax Margin-1,141,542.63% Return on Equity-69.83% Return on Assets-62.35% Debt Debt-to-Equity Ratio0.05 Current Ratio8.59 Quick Ratio8.59 Sales & Book Value Annual Sales$50,000.00 Price / Sales123,305.67 Cash FlowN/A Price / Cash FlowN/A Book Value$10.94 per share Price / Book9.14Miscellaneous Outstanding Shares61,659,000Free Float60,173,000Market Cap$6.17 billion OptionableOptionable Beta0.55 Social Links Key ExecutivesMr. Amit D. Munshi M.B.A. (Age 54)Pres & CEO Comp: $1.22MMs. Laurie D. Stelzer (Age 54)Exec. VP & CFO Comp: $630.76kMr. Vincent E. Aurentz (Age 54)Exec. VP & Chief Bus. Officer Comp: $692.82kDr. Christopher H. Cabell FACCM.D., MHS, AdvisorMr. Robert Lisicki (Age 54)Exec. VP & Chief Commercial Officer Comp: $686.63kDr. Douglas A. Bakan Ph.D.Exec. VP of Technical OperationsDr. Lamine Mbow Ph.D.Sr. VP & Chief Scientific OfficerMegan E. KnightDirector of Investor RelationsPatrick MalloyVP of Investor Relations & Corp. CommunicationsMr. Michael E. Paolucci (Age 62)Exec. VP of HR More ExecutivesKey CompetitorsIonis PharmaceuticalsNASDAQ:IONSMadrigal PharmaceuticalsNASDAQ:MDGLAlkermesNASDAQ:ALKSAmicus TherapeuticsNASDAQ:FOLDIronwood PharmaceuticalsNASDAQ:IRWDView All Competitors ARNA Stock - Frequently Asked Questions Should I buy or sell Arena Pharmaceuticals stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arena Pharmaceuticals in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" ARNA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ARNA, but not buy additional shares or sell existing shares. View ARNA analyst ratings or view top-rated stocks. What is Arena Pharmaceuticals' stock price forecast for 2023? 1 brokerages have issued 12-month target prices for Arena Pharmaceuticals' shares. Their ARNA share price forecasts range from $100.00 to $100.00. On average, they anticipate the company's stock price to reach $100.00 in the next year. This suggests a possible upside of 0.0% from the stock's current price. View analysts price targets for ARNA or view top-rated stocks among Wall Street analysts. How were Arena Pharmaceuticals' earnings last quarter? Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) announced its earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($3.21) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.53) by $0.68. During the same period in the previous year, the company posted ($1.69) EPS. When did Arena Pharmaceuticals' stock split? Arena Pharmaceuticals's stock reverse split on the morning of Monday, June 19th 2017. The 1-10 reverse split was announced on Wednesday, June 14th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 16th 2017. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What is Amit Munshi's approval rating as Arena Pharmaceuticals' CEO? 16 employees have rated Arena Pharmaceuticals Chief Executive Officer Amit Munshi on Glassdoor.com. Amit Munshi has an approval rating of 66% among the company's employees. What other stocks do shareholders of Arena Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Arena Pharmaceuticals investors own include Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), Cytokinetics (CYTK), Micron Technology (MU), NVIDIA (NVDA), Novavax (NVAX), Alibaba Group (BABA), GW Pharmaceuticals (GWPH) and AT&T (T). What is Arena Pharmaceuticals' stock symbol? Arena Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARNA." What is Arena Pharmaceuticals' stock price today? One share of ARNA stock can currently be purchased for approximately $99.99. How much money does Arena Pharmaceuticals make? Arena Pharmaceuticals (NASDAQ:ARNA) has a market capitalization of $6.17 billion and generates $50,000.00 in revenue each year. The biopharmaceutical company earns $-616,430,000.00 in net income (profit) each year or ($10.13) on an earnings per share basis. How many employees does Arena Pharmaceuticals have? The company employs 448 workers across the globe. How can I contact Arena Pharmaceuticals? Arena Pharmaceuticals' mailing address is 6154 Nancy Ridge Drive, San Diego CA, 92121. The official website for the company is www.arenapharm.com. The biopharmaceutical company can be reached via phone at (858) 453-7200, via email at ir@arenapharm.com, or via fax at 858-453-7210. This page (NASDAQ:ARNA) was last updated on 1/28/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.